Targeted monoclonal antibodies like Bevacizumab (Avastin®), which targets the angiogenic VEGF/VEGFR pathway, have been approved as first‐line therapy alone as well as in combination with other chemotherapeutic drugs for patients with advanced CRC [255]. The gene discussed is VEGFA; the disease is colorectal carcinoma.